# Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines

> **NIH NIH R01** · MAYO CLINIC ROCHESTER · 2024 · $369,593

## Abstract

ABSTRACT
Alcohol withdrawal is a critical component of development and persistence of addiction to alcohol and a cause
for significant morbidity and mortality in patients with alcohol use disorders (AUD). Introduction of
benzodiazepines resulted in reduced severity of alcohol withdrawal syndrome (AWS), and decreased mortality
and frequency of complications. While research suggests involvement of certain neurotransmitter systems in
the neurobiology of AWS, genetic markers associated with predisposition to AWS and its treatment response
remain unknown. We therefore propose to perform comprehensive genetic analyses, including genome-wide
association studies (GWASs), to identify genetic markers of AWS risk and response to benzodiazepine
treatment of AWS. The proposed analyses will constitute the largest GWAS of AWS to date, with a sample
size of AUD subjects 10 times larger than the only previously published AWS GWAS, and the first GWAS of
benzodiazepine response. We will also investigate sex differences in genetic effects on AWS and
response to its treatment. Our study will involve advanced analyses, including assessment of SNP-based
heritability of AWS along with gene and pathway-level analyses (including drug-target enrichment) and
fine-mapping to detect relevant genetic effects. We will also use polygenic risk scores to determine if
genetic load for AUD-related traits is associated with AWS. The proposed study is aligned with NIAAA policy,
which states that GWAS is “the preferred approach for the identification of and the confirmation of genes that
harbor variants that contribute to AUD and related phenotypes, since results from these studies will likely
provide potential insights into translational studies and new therapeutic targets”. The proposed research also
supports NIH efforts to increase awareness and attention to sex and gender in research. Our preliminary data
and power calculations demonstrate that analysis of available data is expected to identify common genetic
variants associated with AWS. Discovery of genetic variants that impact the risk of AWS will generate
knowledge on its neurobiology and ultimately contribute to the development of tools for the
identification of patients at risk and selection of treatment options based on an understanding of inter-
individual differences in sensitivity to this central component of AUD. This line of research may also
contribute to development of new AUD treatment approaches aimed to restore physiological
dysfunction associated with those genetic variants.

## Key facts

- **NIH application ID:** 10830242
- **Project number:** 5R01AA030273-02
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Joanna M Biernacka
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $369,593
- **Award type:** 5
- **Project period:** 2023-05-01 → 2027-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10830242

## Citation

> US National Institutes of Health, RePORTER application 10830242, Genomics of Alcohol Withdrawal and Treatment Response to Benzodiazepines (5R01AA030273-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10830242. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*